Ruth Wexler is an American industrial chemist best known as a co-discoverer of apixaban, a marketed anticoagulant; and losartan, a blood pressure treatment.[1]
Ruth R. Wexler | |
|---|---|
| Born | Pikesville, MD |
| Nationality | American |
| Alma mater | University of Pennsylvania |
| Known for | cardiovascular drug development |
| Scientific career | |
| Thesis | (1982) |
| Doctoral advisor | Amos Smith |
Education
editWexler received her B.A. in chemistry from Boston University in 1977, and a Ph.D. in organic chemistry working with Amos B. Smith at the University of Pennsylvania in 1982.[2][3]
Research
editWexler started her career at DuPont in 1982, rising to Executive Director in 1998. She then joined Bristol-Myers Squibb as an Executive Director in 2001, moving eventually to New Jersey to head their cardiovascular research unit.[2] She has worked on targets involved in apoptosis, inflammation, obesity, and coagulation. As of 2018, she has over 215 original research publications.[4]
Awards
edit- 2015 - E.B. Hershberg Award for Discoveries in Medicinally Active Substances[1]
- 2014 - Inducted into the ACS MEDI Hall of Fame[5]
- 2011 - BMS Ondetti and Cushman Award
- 2004 - Outstanding New Jersey Woman in Research
References
edit- ^ a b Jarvis, Lisa. "E. B. Hershberg Award For Important Discoveries In Medicinally Active Substances | Chemical & Engineering News". cen.acs.org. Retrieved 2018-11-21.
- ^ a b "Ruth R. Wexler, Ph.D." www.acsmedchem.org. Retrieved 2018-11-21.
- ^ "Wexler, Ruth | Amos Smith Research Group". www.sas.upenn.edu. Retrieved 2018-11-21.
- ^ Quan, Mimi L.; Pinto, Donald J. P.; Smallheer, Joanne M.; Ewing, William R.; Rossi, Karen A.; Luettgen, Joseph M.; Seiffert, Dietmar A.; Wexler, Ruth R. (2018-05-18). "Factor XIa Inhibitors as New Anticoagulants". Journal of Medicinal Chemistry. 61 (17): 7425–7447. doi:10.1021/acs.jmedchem.8b00173. ISSN 0022-2623. PMID 29775297.
- ^ "MEDI Hall of Fame Inductees". www.acsmedchem.org. Retrieved 2018-11-21.